Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Leukemia research - 1 Aug 2010

Szpurka Hadrian, Jankowska Anna M, Makishima Hideki, Bodo Juraj, Bejanyan Nelli, Hsi Eric D, Sekeres Mikkael A, Maciejewski Jaroslaw P

Abstract excerpt

While a majority of patients with refractory anemia with ring sideroblasts and thrombocytosis harbor JAK2V617F and rarely MPLW515L, JAK2/MPL-negative cases constitute a diagnostic problem. 23 RARS-T cases were investigated applying immunohistochemical phospho-STAT5, sequencing and SNP-A-based karyotyping. Based on the association of TET2/ASXL1 mutations with MDS/MPN we studied molecular pattern of these genes....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Anemia, Sideroblastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dioxygenases

Share to DNA-Binding Proteins

Share to Immunoenzyme Techniques

Share to Proto-Oncogene Proteins

Share to Repressor Proteins

Share to Thrombocytosis

Source

Open in PubMed Open full text

Identifiers

PMID: 20334914
DOI: 10.1016/j.leukres.2010.02.033
PMCID: PMC2953471

Genes

ASXL1
TET2
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.PMID 20334914Read ↗

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutationsSemantic proximity Read ↗

Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosisSemantic proximity Read ↗

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.Semantic proximity Read ↗

Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencingSemantic proximity Read ↗

The role of JAK2 mutations in RARS and other MDS.Semantic proximity Read ↗

Mutations of ASXL1 and TET2 in aplastic anemiaSemantic proximity Read ↗

Refractory anemia with ring sideroblasts and RARS with thrombocytosis.Semantic proximity Read ↗

Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.Semantic proximity Read ↗

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.Semantic proximity Read ↗

Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.Semantic proximity Read ↗

A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.